Haratani [43] found that T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from Nivolumab (anti-human PD-1 monoclonal antibodies) after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, when compared with T790M-positive patients, which indicates that patients with other resistance mechanisms, such as MET activation, may have higher response rates compared with those with T790M mutations in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.